



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 53310

Title: Camrelizumab (SHR-1210), an anti-PD-1 antibody, leading to reactive capillary hemangioma in gingiva: A case report

Reviewer's code: 03998375

Position: Editorial Board

Academic degree: MBChB, MSc

Professional title: Assistant Professor

Reviewer's country: Iraq

Author's country: China

Reviewer chosen by: Artificial Intelligence Technique

Reviewer accepted review: 2019-12-15 19:41

Reviewer performed review: 2019-12-16 19:23

Review time: 23 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Abstract background: More information is required about Camrelizumab (SHR-1210).
Reactive capillary hemangioma in gingiva as a result of Camrelizumab treatment in
previous studies should be mentioned in the Discussion.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 53310

Title: Camrelizumab (SHR-1210), an anti-PD-1 antibody, leading to reactive capillary hemangioma in gingiva: A case report

Reviewer's code: 02728252

Position: Editorial Board

Academic degree: PhD

Professional title: Professor

Reviewer's country: Egypt

Author's country: China

Reviewer chosen by: Le Zhang

Reviewer accepted review: 2019-12-21 07:30

Reviewer performed review: 2019-12-21 08:11

Review time: 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

It is a well written case report entitled "Camrelizumab (SHR-1210), an anti-PD-1 antibody, leading to reactive capillary hemangioma in gingiva". The title should be rephrased to be more clear, the type of staining and a scale bar should be clarified in the histological part.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☒ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☒ No

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 53310

Title: Camrelizumab (SHR-1210), an anti-PD-1 antibody, leading to reactive capillary hemangioma in gingiva: A case report

Reviewer's code: 02653697

Position: Peer Reviewer

Academic degree: MD

Professional title: Research Scientist

Reviewer's country: United States

Author's country: China

Reviewer chosen by: Le Zhang

Reviewer accepted review: 2019-12-22 16:27

Reviewer performed review: 2019-12-22 17:14

Review time: 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input checked="" type="checkbox"/> Grade D: Fair	<input checked="" type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input checked="" type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Anti-PD-1 antibody induced capillary hemangiomas are common. But hemangiomas in the gingiva are not common although there are case reports. There are a few concerns that the authors many want to address in revision. 1. English editing is required; 2. Some subtitles in 'case presentation' section can be removed; 3. According to "After the cessation of nifedipine, the enlargement decreased in size on the palatal surfaces of the maxillary anterior teeth and gradually increased in size on the lingual surfaces of the mandibular anterior teeth. ". It is hard to understand that nifedipine only affected palatal surfaces of the maxillary anterior teeth. If this is true, please discuss this aspect in the second paragraph of discussion section; 4. Again, mechanisms by which Anti-PD-1 antibodies induce capillary hemangiomas need more discussion; 5. What is the last document (an abstract, LBA17) for?

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No